Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions.
Squamous cell carcinoma (SCC) of the lung, a subtype of non-small cell lung cancer (NSCLC), typically arises centrally in the main airways like the bronchi. This cancer variant is predominantly linked to tobacco smoke, being the primary cause of cellular transformation. Smoking accounts for about 80% of lung cancer cases in men and 90% in women, with SCC showing a particularly strong association with smoking compared to other NSCLC types. Additional risk factors include age, family history, exposure to second-hand smoke, and contact with mineral dust, metal particles, or asbestos.
The Squamous Non-Small Cell Lung Carcinoma drugs in development market research report provide comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Squamous Non-Small Cell Lung Carcinoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Squamous Non-Small Cell Lung Carcinoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 22 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Squamous Non-Small Cell Lung Carcinoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Squamous Non-Small Cell Lung Carcinoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Squamous Non-Small Cell Lung Carcinoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Accendatech Co LtdAkeso Inc
amcure GmbH
Amgen Inc
Andarix Pharmaceuticals Inc
AstraZeneca Plc
Coherus BioSciences Inc
CSPC Pharmaceutical Group Ltd
GSK plc
Hummingbird Bioscience Pte Ltd
Immatics NV
Instil Bio Inc
Invectys SA
Laekna Therapeutics Shanghai Co Ltd
Nippon Kayaku Co Ltd
Ribon Therapeutics Inc
Shanghai Junshi Biosciences Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Systimmune Inc
The First Affiliated Hospital of the University of Science and Technology of China
Valo Health LLC
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Squamous Non-Small Cell Lung Carcinoma reports